Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell infusion for steroid-resistant acute GVHD or poor graft function
2007-004310-14Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Dec 2007
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mesenchymal stem cells in Acute Graft-Versus-Host Disease (aGvHD) and poor graft function (PGF), sponsored by Centre Hospitalier Universitaire de Liège. Primary endpoints: Efficacy of MSC infusions and Toxicity of MSC infusions. Started Dec 2007; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)poor graft function (PGF)
Beyond the preview
Go deeper on 2007-004310-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004310-14.